1
|
Zhang H, Yuan F, Qi Y, Liu B, Chen Q. Circulating Tumor Cells for Glioma. Front Oncol 2021; 11:607150. [PMID: 33777749 PMCID: PMC7987781 DOI: 10.3389/fonc.2021.607150] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Accepted: 02/11/2021] [Indexed: 12/13/2022] Open
Abstract
Liquid biopsy has entered clinical applications for several cancers, including metastatic breast, prostate, and colorectal cancer for CTC enumeration and NSCLC for EGFR mutations in ctDNA, and has improved the individualized treatment of many cancers, but relatively little progress has been made in validating circulating biomarkers for brain malignancies. So far, data on circulating tumor cells about glioma are limited, the application of circulating tumor cells as biomarker for glioma patients has only just begun. This article reviews the research status and application prospects of circulating tumor cells in gliomas. Several detection methods and research results of circulating tumor cells about clinical research in gliomas are briefly discussed. The wide application prospect of circulating tumor cells in glioma deserves further exploration, and the research on more sensitive and convenient detection methods is necessary.
Collapse
Affiliation(s)
- Huikai Zhang
- Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Fanen Yuan
- Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Yangzhi Qi
- Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Baohui Liu
- Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Qianxue Chen
- Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China
| |
Collapse
|
2
|
Gao F, Cui Y, Jiang H, Sui D, Wang Y, Jiang Z, Zhao J, Lin S. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget 2018; 7:71330-71340. [PMID: 27517490 PMCID: PMC5342081 DOI: 10.18632/oncotarget.11114] [Citation(s) in RCA: 80] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2016] [Accepted: 07/10/2016] [Indexed: 11/29/2022] Open
Abstract
Brain glioma is the most common primary intracranial tumor characterized by dismal prognosis and frequent recurrence, yet a real-time and reliable biological approach to monitor tumor response and progression is still lacking. Recently, few studies have reported that circulating tumor cells (CTCs) could be detected in glioblastoma multiform (GBM), providing the possibility of its application in brain glioma monitoring system. But its application limits still exist, because the detection rate of CTCs is still low and was exclusively limited to high- grade gliomas. Here, we adopted an advanced integrated cellular and molecular approach of SE-iFISH to detect CTCs in the peripheral blood (PB) of patients with 7 different subtypes of brain glioma, uncovering the direct evidences of glioma migration. We identified CTCs in the PB from 24 of 31 (77%) patients with glioma in all 7 subtypes. No statistical difference of CTC incidence and count was observed in different pathological subtypes or WHO grades of glioma. Clinical data revealed that CTCs, to some extent, was superior to MRI in monitoring the treatment response and differentiating radionecrosis from recurrence of glioma. Conclusively, CTCs is a common property of brain gliomas of various pathological subtypes, which has provided an ultimate paradox for the hypothesis “soil and seed”. It can be used to monitor the microenvironment of gliomas dynamically, which will be a meaningful complement to radiographic imaging.
Collapse
Affiliation(s)
- Faliang Gao
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China.,Institute for Brain Disorders and Beijing Key Laboratory of Brian Tumor, Beijing, China
| | - Yong Cui
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China.,Institute for Brain Disorders and Beijing Key Laboratory of Brian Tumor, Beijing, China
| | - Haihui Jiang
- Department of Neurosurgery, First Hospital of Tsinghua University, Beijing, China
| | - Dali Sui
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China.,Institute for Brain Disorders and Beijing Key Laboratory of Brian Tumor, Beijing, China
| | - Yonggang Wang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China.,Institute for Brain Disorders and Beijing Key Laboratory of Brian Tumor, Beijing, China
| | - Zhongli Jiang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China.,Institute for Brain Disorders and Beijing Key Laboratory of Brian Tumor, Beijing, China
| | - Jizong Zhao
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China.,Institute for Brain Disorders and Beijing Key Laboratory of Brian Tumor, Beijing, China
| | - Song Lin
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.,China National Clinical Research Center for Neurological Diseases, Beijing, China.,Institute for Brain Disorders and Beijing Key Laboratory of Brian Tumor, Beijing, China
| |
Collapse
|
3
|
Ge F, Zhang H, Wang DD, Li L, Lin PP. Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells. Oncotarget 2016; 6:27049-64. [PMID: 26267323 PMCID: PMC4694973 DOI: 10.18632/oncotarget.4819] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 07/17/2015] [Indexed: 12/27/2022] Open
Abstract
Conventional strategy of anti-EpCAM capture and immunostaining of cytokeratins (CKs) to detect circulating tumor cells (CTCs) is limited by highly heterogeneous and dynamic expression or absence of EpCAM and/or CKs in CTCs. In this study, a novel integrated cellular and molecular approach of subtraction enrichment (SE) and immunostaining-FISH (iFISH) was successfully developed. Both large or small size CTCs and circulating tumor microemboli (CTM) in various biofluid samples including cerebrospinal fluid (CSF) of cancer patients and patient-derived-xenograft (PDX) mouse models were efficiently enriched and comprehensively identified and characterized by SE-iFISH. Non-hematopoietic CTCs with heteroploid chromosome 8 were detected in 87–92% of lung, esophageal and gastric cancer patients. Characterization of CTCs performed by CK18-iFISH showed that CK18, the dual epithelial marker and tumor biomarker, was strong positive in only 14% of lung and 24% of esophageal CTCs, respectively. Unlike conventional methodologies restricted only to the large and/or both EpCAM and CK positive CTCs, SE-iFISH enables efficient enrichment and performing in situ phenotypic and karyotypic identification and characterization of the highly heterogeneous CTC subtypes classified by both chromosome ploidy and the expression of various tumor biomarkers. Each CTC subtype may possess distinct clinical significance relative to tumor metastasis, relapse, therapeutic drug sensitivity or resistance, etc.
Collapse
Affiliation(s)
- Feng Ge
- Department of Thoracic Surgery, Capital Medical University School of Oncology and Chaoyang Hospital, Beijing, China
| | - Haishi Zhang
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
| | | | - Linda Li
- Cytelligen, San Diego, California, USA
| | | |
Collapse
|
4
|
Lin PP. Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells. Clin Transl Med 2015; 4:38. [PMID: 26718583 PMCID: PMC4696935 DOI: 10.1186/s40169-015-0081-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Accepted: 12/17/2015] [Indexed: 12/23/2022] Open
Abstract
Application of tumor cell surface adhesion molecule Anti-epithelial cell adhesion molecule (EpCAM)-dependent antibody capture, and intracellular cytokeratins (CKs)-dependent immunostaining strategies to detect disseminated or circulating tumor cells (DTCs or CTCs), is limited by highly heterogeneous and dynamic expression or absence of EpCAM and/or CKs in CTCs and DTCs, particularly in their capturing and identifying CTCs/DTCs shed from diverse types of solid tumor, thus being biased and restricted to the only both EpCAM and CK positive cancer cells. Moreover, heterogeneity of chromosome and tumor biomarker of CTCs/DTCs cannot be co-examined by conventional CK/EpCAM-dependent techniques. Accordingly, a novel integrated cellular and molecular approach of EpCAM-independent subtraction enrichment (SE) and immunostaining-FISH (iFISH(®)) has recently been successfully developed. SE-iFISH(®) is able to effectively enrich, comprehensively identify and characterize both large and small size non-hematopoietic heteroploid CTCs, DTCs and circulating tumor microemboli in various biofluid specimens of either cancer patients or patient-derived-xenograft mice. Obtained tumor cells, free of anti-EpCAM perturbing and hypotonic damage, are eligible for primary tumor cell culture as well as a series of downstream analyses. Highly heterogeneous CTCs and DTCs could be classified into subtypes by in situ phenotyping protein expression of various tumor biomarkers and karyotyping of chromosome aneuploidy performed by iFISH(®). Each CTC subtype may correlate with distinct clinical significance in terms of tumor metastasis, relapse, therapeutic drug sensitivity or resistance, respectively.
Collapse
|
5
|
Ge F, Wang DD, Li L, Lin PP, Shuman MA. WITHDRAWN: Enhanced Detection and Phenotypic and Karyotypic in Situ Characterization of Circulating Tumor Cells. THE AMERICAN JOURNAL OF PATHOLOGY 2014:S0002-9440(14)00536-7. [PMID: 25451150 DOI: 10.1016/j.ajpath.2014.08.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Revised: 08/01/2014] [Accepted: 08/20/2014] [Indexed: 11/28/2022]
Abstract
Available online October 16, 2014 This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Collapse
Affiliation(s)
- Feng Ge
- Department of Thoracic Surgery, Capital Medical University School of Oncology and Shi-Ji-Tan Hospital, Beijing, China
| | - Daisy D Wang
- Department of Translational Oncology, Cytelligen, San Diego, California
| | - Linda Li
- Department of Translational Oncology, Cytelligen, San Diego, California
| | - Peter P Lin
- Department of Translational Oncology, Cytelligen, San Diego, California
| | - Marc A Shuman
- UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco School of Medicine, San Francisco, California
| |
Collapse
|
9
|
Oztürk K, Acar H, Durmuş E, Oztürk A, Mutlu N. Analysis of chromosomes 8 and 17 aneuploidies in laryngeal squamous cell carcinoma by fluorescence in situ hybridization. Laryngoscope 2004; 114:1005-10. [PMID: 15179203 DOI: 10.1097/00005537-200406000-00009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES/HYPOTHESIS The objectives were to investigate chromosomes 8 and 17 numerical aberrations by using fluorescence in situ hybridization in laryngeal squamous cell carcinoma and also to determine whether there is any association between chromosomes 8 and 17 aneuploidies and TNM classification and subgroups of laryngeal squamous cell carcinomas. STUDY DESIGN Descriptive study. METHODS Tumor and control samples were taken from 23 patients with LSCC by surgical operation. Fluorescence in situ hybridization analysis with chromosomes 8- and 17-specific alpha-satellite DNA probes was performed on the interphase nuclei. RESULTS The percentages for chromosomes 8 and 17 aneuploidies were 33% (SD = 25.7%) (median value, 26.2%; range, 3.5%-81.8%) and 19.2% (SD = 15.8%) (median value, 9.8%; range, 3.6%-63.7%), respectively. There was a significant difference between stage 2 and stage 3 (P <.05) and between stage 2 and stage 4 for chromosome 8 aneuploidy (P <.05) but not for chromosome 17 aneuploidy (P >.05). There was also a significant difference for the T classification for chromosome 8 aneuploidy (P <.05) but not for chromosome 17 (P >.05). CONCLUSION Chromosome 8 aneuploidy may be related to stage and T classification of laryngeal squamous cell carcinoma and its progression.
Collapse
Affiliation(s)
- Kayhan Oztürk
- Departments of Otolaryngology, Meram Medical Faculty, Selçuk University, Konya, Turkey.
| | | | | | | | | |
Collapse
|